DDInter992 DDInter1376
A beta-adrenergic agonist that causes direct relaxation of uterine and vascular smooth muscle. Its vasodilating actions are greater on the arteries supplying skeletal muscle than on those supplying skin. It is used in the treatment of peripheral vascular disease and in premature labor.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Isoxsuprine {u} (Compound) resembles {v} (Compound) Monobenzone
Isoxsuprine {u} (Compound) resembles {v} (Compound) Pseudoephedrine
Isoxsuprine {u} (Compound) upregulates {v} (Gene) RRP8
Isoxsuprine {u} (Compound) downregulates {v} (Gene) ATP6V1D
Isoxsuprine {u} (Compound) causes {v} (Side Effect) Hypoglycaemia
Isoxsuprine (Compound) resembles Monobenzone (Compound)
Isoxsuprine (Compound) resembles Pseudoephedrine (Compound)
Isoxsuprine (Compound) upregulates RRP8 (Gene)
Isoxsuprine (Compound) downregulates ATP6V1D (Gene)
Isoxsuprine (Compound) causes Hypoglycaemia (Side Effect)